Loading clinical trials...
Loading clinical trials...
Phase II Trial of Alpelisib With iNOS Inhibitor and Nab-paclitaxel in Patients With HER2 Negative Metastatic or Locally Advanced Metaplastic Breast Cancer (MpBC)
Conditions
Interventions
L-NMMA
Locations
3
United States
National Institute of Health Clinical Center
Bethesda, Maryland, United States
Houston Methodist Neal Cancer Center
Houston, Texas, United States
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Start Date
January 12, 2023
Primary Completion Date
December 1, 2026
Completion Date
December 2, 2028
Last Updated
April 3, 2026
NCT05467891
NCT07354022
NCT02422641
NCT07483307
NCT06625775
NCT06649331
Lead Sponsor
The Methodist Hospital Research Institute
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions